BIOCORP, a French company specializing in the development and manufacturing of innovative medical and drug delivery devices (FR12788065 — ALCOR / PEA-PME eligible) introduces Easylog, its new add-on to improve diabetic patients’ adherence to insulin injections. The first internet-connected system of its kind, Easylog attaches to the insulin pen, which, with 51.5 million users worldwide and an average annual growth of 13%, is now the most popular mode of treatment among diabetic patients*.

Easylog, a smart sensor for insulin delivery systems

“Having gained recognition with our innovative DataPen, the first-ever smart injection pen, we intensified our R&D efforts with the intention to expand the scope of our disruptive technologies to dynamic markets with strong growth potential. Today, this strategy allows us to provide manufacturers with a practical, internetconnected, easy-to-use solution that is compatible with existing insulin delivery devices and meets the challenges of personalized medicine. With this innovation, we seek once again to promote a better management of chronic diseases by bringing comfort to patients, empowering doctors and caregivers to ensure that the right treatments are given at the right time with the right dose, and by creating value for our pharmaceutical partners,” said Jacques Gardette, Biocorp’s President and founder.

A unique, patented technology whose design has been registered — a prototype of which was unveiled at the 2015 annual meeting of the European Association for the Study of Diabetes, in mid-September in Stockholm — EasyLog is an intelligent sensor that converts all insulin delivery devices, reusable as well as disposable, into internet-connected and communicating devices.

The data collected (insulin doses, patients’ vital signs, etc.) are encrypted and made anonymous thanks to Biocorp’s extensive know-how in health data security.

These data are first stored on servers belonging to a secured and government-certified web host before being safely transferred to a mobile app similar to the one used for DataPen. This application provides users with treatment reminders, alerts in case of a risk of insulin overdose, and access to patients’ historical data, among other services. Thanks to this real-time monitoring of the treatment, the patient is empowered to adhere to his treatment, while the medical staff can tailor individual treatment recommendations.

Follow us on Twitter.

* Source: Insulin Pen Market, Users (reusable & prefilled) & forecast, Worldwide analysis, Renub Research, 2014